生物制品药品通用名称命名的研究进展  

Advance in study on general principles of nomenclature of biologicals in China

作　　者：任跃明[1] 张仕斌[1] 

机构地区：[1]国家药典委员会,北京100061

出　　处：《中国生物制品学杂志》2014年第6期865-867,872,共4页Chinese Journal of Biologicals

摘　　要：生物制品的药品通用名称管理是一项有意义的工作,规范药品的名称对加强药品的监督管理及维护公共健康利益至关重要。我国生物制品虽有其命名原则,但是较为复杂,有待规范化。本文对我国目前生物制品药品通用名称的命名原则、进展及存在的问题作一综述。The management of drug name is of an important significance, of which the standardization is the key to strengthening the surveillance of drugs and protecting the public health. The current General Principles of Nomenclature of Biologica!s is complicated, which needs to be further standardized. This paper reviews the principles, advances and problems in nomenclature of therapeutic biotherapeutics in China.

关 键 词：生物制品 生物技术类生物制品 通用名称 

分 类 号：R392.33[医药卫生—免疫学]